Table 2. DASISION 3-year mutational analysis.
| Dasatinib 100 mg once daily, N=259 | Imatinib 400 mg once daily, N=260 | |
|---|---|---|
| Patients identified for mutational analysis, n (%) | 169 (65) | 194 (75) |
| Patients with samples analyzed for mutations, n | 155 | 183 |
| Patients with samples not analyzed,a n | 14 | 11 |
| Patients with mutations detected (total), n | 17 | 18 |
| Mutations detectedb (n) | G250E (1), V299L (3), T315I (11), F317I/L (3) | M244V (1), L248V (1), G250E (3), Y253H (1), E255K/V (4), D276G (1), M351T (3), E355G (2), F359C/I/V (5), L387M (1), H396P (1), E450G (1) |
Abbreviation: DASISION, Dasatinib versus Imatinib Study in Treatment-Naive CML-CP.
a
Alternate transcript; BCR-ABL1 too low to test; other.
b
Includes patients with two mutations: one dasatinib (V299L/F317I) and six imatinib (L248V/E355G, E255V/E450G, E255K/M351T, Y253H/E255V, D276G/F359C and M351T/F359V).